CVS Health Corp (CVS) Stake Boosted by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its stake in CVS Health Corp (NYSE:CVS) by 41.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 397,309 shares of the pharmacy operator’s stock after purchasing an additional 116,589 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in CVS Health were worth $32,309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sabal Trust CO raised its position in CVS Health by 7.3% in the 3rd quarter. Sabal Trust CO now owns 293,347 shares of the pharmacy operator’s stock worth $23,855,000 after buying an additional 19,916 shares during the last quarter. Alpha Windward LLC raised its position in CVS Health by 170.9% in the 3rd quarter. Alpha Windward LLC now owns 9,441 shares of the pharmacy operator’s stock worth $768,000 after buying an additional 5,956 shares during the last quarter. Arcadia Investment Management Corp MI raised its position in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after buying an additional 726 shares during the last quarter. Assenagon Asset Management S.A. raised its position in CVS Health by 130.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 24,269 shares of the pharmacy operator’s stock worth $1,974,000 after buying an additional 13,742 shares during the last quarter. Finally, Culbertson A N & Co. Inc. raised its position in CVS Health by 1.1% in the 3rd quarter. Culbertson A N & Co. Inc. now owns 110,184 shares of the pharmacy operator’s stock worth $8,960,000 after buying an additional 1,218 shares during the last quarter. 81.63% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on CVS shares. Needham & Company LLC reissued a “hold” rating on shares of CVS Health in a research report on Sunday, September 10th. Oppenheimer reissued a “buy” rating and issued a $95.00 target price on shares of CVS Health in a research report on Monday, October 9th. Leerink Swann reissued an “outperform” rating and issued a $85.00 target price (down previously from $90.00) on shares of CVS Health in a research report on Tuesday, November 7th. BidaskClub lowered CVS Health from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Finally, SunTrust Banks set a $85.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $86.35.

CVS Health Corp (NYSE:CVS) opened at $71.67 on Tuesday. The stock has a market capitalization of $74,029.46, a P/E ratio of 12.80, a P/E/G ratio of 1.37 and a beta of 0.89. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. CVS Health Corp has a 52 week low of $66.45 and a 52 week high of $84.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.64 EPS. research analysts predict that CVS Health Corp will post 5.9 earnings per share for the current year.

In related news, EVP Thomas M. Moriarty sold 20,547 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total transaction of $1,667,799.99. Following the completion of the transaction, the executive vice president now directly owns 43,178 shares in the company, valued at approximately $3,504,758.26. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.61% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CVS Health Corp (CVS) Stake Boosted by Robeco Institutional Asset Management B.V.” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/12/19/cvs-health-corp-cvs-stake-boosted-by-robeco-institutional-asset-management-b-v.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply